PROCEPT BioRobotics develops Aquablation therapy, a robotic, image-guided waterjet procedure for treating benign prostatic hyperplasia (BPH). Its systems aim to remove prostate tissue with heat-free resection, combining real-time imaging with automated robotics for urologists. Hospitals and surgical centers use the platform as a specialized alternative to traditional surgical BPH treatments.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 79.2 | — | -19.6 | — |
| Q3 2025 | 83.3 | — | -21.4 | — |
| Q4 2025 | 76.4 | — | -29.8 | — |
| Q1 2026 | 83.1 | — | -31.6 | — |
| Q2 2026 | 94.5 | 19.3% | -26.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: LGI Homes, Inc. (LGIH), Horizon Bancorp, Inc. (HBNC), The Simply Good Foods Company (SMPL), Ituran Location and Control Ltd. (ITRN), MannKind Corporation (MNKD), Vor Biopharma Inc. (VOR)